Dr. Schadendorf Discusses Sequencing Agents in Melanoma
Dirk Schadendorf, MD
Dirk Schadendorf, MD, head of department for Dermatology, Venerology and Allergology, University Hospital Essen, Germany, discusses sequencing agents in melanoma.
Schadendorf says that it is currently unclear whether administering combination therapy upfront or beginning with targeted therapy and maintaining response by using a checkpoint blockade is more beneficial. There are ongoing clinical trials evaluating these strategies, but there is a waiting period.